Eli Lilly and Seamless Therapeutics Forge $1.12 Billion Alliance to Pioneer Programmable Recombinase Gene Therapies for Genetic Hearing Loss
DRESDEN, GERMANY & LEXINGTON, MASS – January 29, 2026 – In a significant move set to accelerate the development of advanced genetic medicines, Seamless Therapeutics, a German-based gene-editing innovator, today…
